Indian Journal of Research in Homeopathy

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 8  |  Issue : 2  |  Page : 112--118

Clinical evaluation of autologous platelet-rich fibrin and perioglas® in treating periodontal intrabony defects


Shravanthi Raghav Yajamanya, Anirban Chatterjee 
 Department of Periodontology and Oral Implantology, The Oxford Dental College, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Shravanthi Raghav Yajamanya
Department of Periodontology and Oral Implantology, The Oxford Dental College, Bengaluru, Karnataka
India

Context: This study was conducted to compare autologous platelet-rich fibrin (PRF) with PerioGlas® in treating periodontal intrabony defects (IBDs) of variable number of walls, based on clinical and radiographic outcomes. Aim: The aim of the study was to assess which regenerative material, i.e., autologous PRF or PerioGlas®, has a broader range of applicability in treating periodontal IBDs. Settings and Design: This study is a randomized controlled trial conducted at the Department of Periodontology and Oral Implantology of the Oxford Dental College and Hospital, Bangalore, India. Methods: Sixty IBDs were provided nonsurgical periodontal treatment, i.e., scaling and root planing, followed by oral hygiene instructions. When performing periodontal surgery, the IBDs were assigned to the Control group (i.e., access flap alone), test Group I (i.e., access flap + (PerioGlas®), and test Group II (i.e., access flap + autologous PRF). The vertical bone defects in three groups consisted of 3-, 2-, and 1-wall intrabony periodontal defects. Radiographic assessments were performed at baseline and 6 and 9 months. Statistical Analysis Used: Statistical analysis was based on the mean values, standard deviation, and P values. Results: Mean defect depth fill compared to baseline and 9 months postoperatively for: (1) 3-wall IBDs: Control group was 6.50 ± 1.56 mm, test Group I was 9.27 ± 1.62 mm, and test Group II was 10.45 ± 2.33 mm, (2) 2-wall IBDs: Control group was 6.08 ± 0.62 mm, test Group I was 8.21 ± 1.58 mm, and test Group II was 8.96 ± 1.85 mm, and (3) 1-wall IBDs: Control group was 5.78 ± 1.07 mm and test Group II was 8.00 ± 0.69 mm. Conclusion: Autologous PRF has a wider applicability in case of various types of IBDs as compared to PerioGlas® owing to its mechanism of action and composition which is the presence of various growth factors and cytokines.


How to cite this article:
Yajamanya SR, Chatterjee A. Clinical evaluation of autologous platelet-rich fibrin and perioglas® in treating periodontal intrabony defects.Niger J Exp Clin Biosci 2020;8:112-118


How to cite this URL:
Yajamanya SR, Chatterjee A. Clinical evaluation of autologous platelet-rich fibrin and perioglas® in treating periodontal intrabony defects. Niger J Exp Clin Biosci [serial online] 2020 [cited 2021 Apr 17 ];8:112-118
Available from: https://www.njecbonline.org/article.asp?issn=2348-053X;year=2020;volume=8;issue=2;spage=112;epage=118;aulast=Yajamanya;type=0